🔎 Trials Near Me

Home › Esophageal Adenocarcinoma › Oregon › Portland

Esophageal Adenocarcinoma clinical trials in Portland, OR

6 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

RecruitingPhase 2/3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

RecruitingPhase 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · 12 mi away
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05677490

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

RecruitingPhase 1
  • Providence Cancer Institute Franz Clinic, Portland
  • Providence Oncology and Hematology Care Clinic - Westside, Portland
  • Providence St. Vincent Medical Center- Investigational Drug Services, Portland
  • and 1 more
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

RecruitingPhase 2
  • VA Portland Health Care System, Portland, OR, Portland
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT05563766

Esophageal Adenocarcinoma trials in other cities

Other studies in Portland

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.